- Tislelizumab (TIS) versus sorafenib (SOR) in first-line (1L) treatment of unresectable hepatocellular carcinoma (HCC): The RATIONALE-301 Chinese subpopulation analysisQin, S.; Guo, Y.; Meng, Z.; Wu, J.; Gu, K.; Zhang, T.; Lin, X.; Lin, H.; Ying, J-E.; Zhou, F.; Hsing-Tao, K.; Chao, Y.; Li, S.; Chen, Y.; Boisserie, F.; Abdrashitov, R.; Bai, Y.ESMO Asia Congress, Singapore, SINGAPORE, 2022-12-02 To 2022-12-04.被引 1
- Tislelizumab monotherapy for patients with previously treated advanced hepatocellular carcinoma (HCC): RATIONALE-208 Chinese subpopulationRen, Z.; Li, Z.; Zhang, T.; Fang, W.; Hu, S.; Pan, H.; Yen, C.; Hou, J.; Chen, Y.; Shao, G.; Hsu, C.; Bai, Y.; Meng, Z.; Hou, M.; Xie, C.; Liu, Y.; Wu, J.; Li, B.; Chica-Duque, S.; Cheng, A.被引 2
- Clinical outcomes in patients (pts) with previously treated advanced hepatocellular carcinoma (HCC) experiencing hepatitis B virus (HBV) DNA increases during tislelizumab (TIS) treatment in RATIONALE-208Cheng, Ann-Lii; Hou, Jinlin; Fang, Weijia; Li, Zhiwei; Hu, Sheng; Pan, Hongming; Chen, Yajin; Hsu, Chiun; Bai, Yuxian; Meng, Zhiqiang; Hou, Ming-Mo; Xie, Congying; Liu, Yong; Wu, John; Li, Bai; Chica-Duque, Sandra; Ren, ZhenggangASCO Gastrointestinal Cancers Symposium, San Francisco, CA, 2022-01-20 To 2022-01-22.
会议论文
Final analysis of RATIONALE-301: Randomized, phase III study of tislelizumab versus sorafenib as first-line treatment for unresectable hepatocellular carcinoma
45被引19阅读
